CME online

in association with the 3rd Heart in Diabetes

The Primary Prevention of CHF and CKD in Diabetes

This is a CME Symposium Supported by an Educational Grant from AstraZeneca
Provided By:
This CME online educational activity is approved for a maximum of 2 AMA PRA Category 1 Credits ™.
Accreditation period: August 16, 2019 – August 16, 2020

To get started:

Login / Register
CME information
View Agenda
Course presentation

To Receive a Certificate for This CME Activity:  

View the presentations in this CME activity and complete the evaluation. Your certificate will be mailed to you upon satisfactory completion of these documents.

The Primary Prevention of CHF and CKD in Diabetes
Agenda

Introduction / Pre- CME Questions
Yehuda Handelsman, MD ● Mikhail N. Kosiborod, MD

Major Complications of Diabetes: Epidemiology of CHF and CKD
Maria Rosa Costanzo, MD

The Fatal Connection - Diabetes, the Kidney, and the Heart: The Cardiorenal Syndrome
Peter A. McCullough, MD

Contemporary Approach to Preventing CHF in Diabetes: Focus on Primary Prevention
Javed Butler, MD, PhD

The Role of SGLT2 Inhibitors in the Prevention and Management of CKD in Diabetes
George L. Bakris, MD

Panel Discussion and Q&A:
Treatment of Diabetes in 2020 - Preferred Medications to Prevent Complications
Panel: George L. Bakris, MD ● Javed Butler, MD ● Mark E. Cooper, AO, PhD ● Maria Rosa Costanzo, MD ● Peter A. McCullough, MD ● Matthew R. Weir, MD
Moderators: Yehuda Handelsman, MD ● Mikhail N. Kosiborod, MD

Faculty

Yehuda Handelsman, MD, FACP, FNLA, MACE

Chair & Program Director
17th WCIRDC & 3rd HiD
Medical Director & Principal Investigator,
Metabolic Institute of America
Chair & Founder, International Committee for Insulin Resistance
Chair & Founder International Lipid Forum
Tarzana, California

George L. Bakris, MD, MA, Hon. DSc, FASN, FAHA

Professor of Medicine (tenured)
Director, AHA Comprehensive Hypertension Center
The University of Chicago Medicine
Chicago, Illinois

Javed Butler, MD, MPH, MBA

Professor of Medicine
Department of Medicine
University of Mississippi Medical Center
Oxford, Mississippi

Mark E. Cooper, AO, MB BS, PhD, FRACP, FAHMS

Head, Department of Diabetes
Central Clinical School
Monash University
Senior Endocrinologist, Alfred Health Clinic
Melbourne, Australia

Maria Rosa Costanzo, MD, FAHA, FACC, FESC

Medical Director, Heart Failure Research, Advocate Heart Institute
Medical Director, Edward Hospital Center for Advanced Heart Failure
Naperville, Illinois

Mikhail N. Kosiborod MD, FACC, FAHA

Professor of Medicine
Saint Luke's Mid America Heart Institute
University of Missouri-Kansas City School of Medicine
Kansas City, Missouri

Peter A. McCullough, MD, MPH, FACC, FACP, FCCP, FAHA, FNKF, FCRSA

Vice Chief of Medicine
Baylor University Medical Center
Dallas, Texas

Matthew R. Weir, MD

Professor and Chief
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland

Program Description

Diabetes, chronic kidney disease (CKD), and congestive heart failure (CHF)- The CardioRenal Syndrome- share common pathophysiologic origins including hypertension, inflammation, and increased renin-angiotensin-aldosterone system activity. The risk of CHF & CVD is 2-8 times higher if patients have both diabetes and CKD, and over half of heart failure patients have moderate to severe CKD.

In recent cardiovascular outcomes trials (CVOTs), sodium glucose cotransporter 2 (SGLT2) inhibitors showed a Primary and Secondary prevention of CHF and CKD. These findings have highlighted the pathophysiologic contributions of CKD in the development of CHF and CVD, presenting an important approach to reducing patients’ overall cardiovascular risk.

This enduring CME activity recorded from live symposium at 3rd Heart in Diabetes Congress will examine and review the optimal approaches to preventing the onset and progression of CKD and CHF in patients with diabetes.


Learning Objectives

Upon completion of this meeting, participants should be able to:

  • Describe the prevalence, disease burden, and treatment challenges of CHF and CKD in patients with diabetes
  • Describe how the cardiorenal syndrome contributes to the development of CHF- and CVD-related morbidity and mortality in patients with diabetes
  • Compare and contrast the effects of different antihyperglycemic agents on heart failure risk in primary vs secondary prevention populations
  • Discuss the effects of SGLT2 inhibition on kidney function and CKD risk in patients with diabetes
  • Design optimal therapeutic regimens for the prevention of CKD and CHF in patients with diabetes

    • Target Audience

    This educational initiative is designed for cardiologists, endocrinologists, family physicians, internists, diabetologists, nurse practitioners, physician assistants, diabetes educators, and other healthcare professionals interested in the pathophysiology, prevention, and treatment of diabetes, obesity, cardiovascular disease, and associated conditions, as well as the effects of these conditions on health and society.

    CME Statement

    This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI, Inc and Metabolic Endocrine Education Foundation (MEEF).

    PESI Inc is accredited by the ACCME to provide continuing medical education for physicians.

    PESI Inc designated this live educational activity for a maximum of 2 AMA PRA Category 1 Credits ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    This is a CME Program Supported by an Educational Grant from AstraZeneca
    Jointly Provided by    : MEEF & PESI